CELSENTRI 150 MG — DIN 02299844
MARAVIROC : 150 MG · VIIV HEALTHCARE ULC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is CELSENTRI?
CELSENTRI 150 MG contains MARAVIROC : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02299844, held by VIIV HEALTHCARE ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 30-Aug-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CELSENTRI used for?
CELSENTRI (maraviroc), in combination with other antiretroviral agents, is indicated for adult patients infected with CCR5 - tropic HIV - 1. CCR5 tropism should be confirmed using a highly sensitive tropism assay prior to initiation of CELSENTRI therapy. CELSENTRI is not recommended in patients infected with dual/mixed - or CXCR4 - tropic HIV - 1; efficacy in this patient population was not demonstrated in a Phase 2 Study.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Maraviroc cost around the world?
Maraviroc is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Italy | ex-factory (classe H) | 5 | 7 | EUR███.██ |
| United States | acquisition | 2 | 6 | USD███.██ |
| Australia | ex-manufacturer | 2 | 4 | AUD███.██ |
| Romania | max producer price | 4 | 4 | RON███.██ |
| Saudi Arabia | public | 2 | 4 | SAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 1 | 2 | CZK███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Hungary | producer price (ex-factory) | 2 | 2 | HUF███.██ |
| Luxembourg | reimbursement | 2 | 2 | EUR███.██ |
| South Africa | single exit price | 2 | 2 | ZAR███.██ |
37 pack listings across 26 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Maraviroc pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Maraviroc in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Maraviroc — 2 DINs, of which 2 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| VIIV HEALTHCARE ULC | 2 | 2 | CELSENTRI | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | CELSENTRI tablets are supplied in high density polyethylene bottles (HDPE) with polypropylene child resistant (CR) closures and an aluminium foil/polyethylene heat induction seal containing 30, 60, 120 and 180 film - coated tablets. CELSENTRI tablets are supplied in polyvinyl chloride (PVC) blisters with aluminium foil backing in a carton containing 30, 60, 90 and 180 (2 x 90) film - coated tablets. |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Maraviroc |
|---|---|
| ATC code | J05AX09 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02299844 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2299844 |
| Brand name | CELSENTRI |
| Generic / active ingredient | MARAVIROC : 150 MG |
| Market authorization holder | VIIV HEALTHCARE ULC |
| Health Canada schedule | Prescription |
| ATC code | J05AX09 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AX |
| Current status | MARKETED |
| Status date | 30-Aug-2014 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CELSENTRI | 300 MG | TABLET | VIIV HEALTHCARE ULC | MARKETED | 02299852 |
2 · Same class — other molecules in ATC J05AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Baloxavir Marboxil | XOFLUZA | 3 | 3 | Yes |
| Other Antivirals | PREVYMIS | 2 | 2 | Yes |
| Lenacapavir | SUNLENCA | 2 | 2 | Yes |
| Maraviroc | CELSENTRI | 2 | 2 | Yes |
| Inosine Pranobex | IMUNOVIR · ISOPRINOSINE · ISOPRINOSINE TAB 500MG | 4 | 1 | Yes |
| Letermovir | PREVYMIS | 2 | 1 | Yes |
| Maribavir | LIVTENCITY | 1 | 1 | Yes |
| Bulevirtide | HEPCLUDEX | 1 | 1 | Yes |
| Fostemsavir | RUKOBIA | 1 | 1 | Yes |
| Enfuvirtide | FUZEON | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · Remdesivir · Valaciclovir · Valganciclovir | 143 | 55 |
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · Emtricitabine, Tenofovir Alafenamide And Bictegravir · Emtricitabine, Tenofovir Alafenamide And Rilpivirine · Emtricitabine, Tenofovir Alafenamide, Darunavir And Cobicistat · Emtricitabine, Tenofovir Alafenamide, Elvitegravir And Cobicistat · Emtricitabine, Tenofovir Disoproxil And Efavirenz · Emtricitabine, Tenofovir Disoproxil And Rilpivirine · Emtricitabine, Tenofovir Disoproxil, Elvitegravir And Cobicistat · Lamivudine And Abacavir · Lamivudine And Dolutegravir · Lamivudine, Abacavir And Dolutegravir · Lamivudine, Tenofovir Disoproxil And Doravirine · Lopinavir And Ritonavir · Tenofovir Disoproxil And Emtricitabine · Zidovudine And Lamivudine · Zidovudine, Lamivudine And Abacavir · Zidovudine, Lamivudine And Nevirapine | 56 | 39 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · Lamivudine · Stavudine · Telbivudine · Tenofovir Alafenamide · Tenofovir Disoproxil · Zalcitabine · Zidovudine | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · Nelfinavir · Nirmatrelvir And Ritonavir · Ritonavir · Saquinavir · Tipranavir | 75 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · Rilpivirine | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · Glecaprevir And Pibrentasvir · Ombitasvir, Paritaprevir And Ritonavir · Ribavirin · Simeprevir · Sofosbuvir · Sofosbuvir And Ledipasvir · Sofosbuvir, Velpatasvir And Voxilaprevir · Telaprevir | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CELSENTRI called?
The same molecule, Maraviroc, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Maraviroc Waymade | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.